ABSTRACT
Multiple autoimmune syndrome is a rare condition, described by Humbert and Dupond in 1988. It is defined by the association of at least 3 autoimmune diseases in the same patient. Vitiligo is the most common skin condition in this syndrome. This article presents the case of a 31-year-old male with vitiligo, alopecia areata, Crohn's disease, psoriasis vulgaris and oral lichen planus. The rarity of this case is highlighted by the coexistence of four autoimmune skin diseases in association with Crohn's disease, never described in the literature.
Subject(s)
Humans , Male , Adult , Psoriasis/pathology , Autoimmune Diseases/pathology , Vitiligo/pathology , Crohn Disease/pathology , Lichen Planus, Oral/pathology , Alopecia Areata/pathology , Psoriasis/complications , Autoimmune Diseases/complications , Syndrome , Vitiligo/complications , Crohn Disease/complications , Lichen Planus, Oral/complications , Alopecia Areata/complicationsABSTRACT
Cutaneous involvement associated to multiple myeloma varies from 5 to 10% of cases and is infrequently recognized. Cutaneous metastatic plasmacitomas are rare. We present the case of a 72-year-old man with multiple myeloma in complete remission since 2 years ago with cutaneous tumors on the trunk and face. A cutaneous biopsy was consistent with plasmacytoma. The patient was treated with melphalan, prednisolone and radiotherapy. Despite optimal therapeutic response of the lesions, the disease progressed, with the appearance of new extra-cutaneous plasmocytomas. The cutaneous metastatic plasmocytomas were the first sign of progression of the disease.
Subject(s)
Humans , Male , Aged , Plasmacytoma/secondary , Skin Neoplasms/secondary , Multiple Myeloma/pathology , Skin/pathology , Biopsy , Bone Marrow/pathology , Immunohistochemistry , Disease ProgressionABSTRACT
The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.
Os efeitos paradoxais dos anti-TNF-alpha têm sido cada vez mais descritos com a utilização mais ampla dessas drogas. Entre os TNF-alpha, registam-se poucos casos com a utilização de adalimumab no tratamento da sarcoidose cutânea, sendo que todos eles apresentam bons resultados. Têm sido descritos, mais recentemente, casos de sarcoidose induzidos por vários anti-TNF-alpha. O presente caso é, até à data, o primeiro a descrever a exacerbação de lesões cutâneas de sarcoidose tratadas com adalimumab.